DSGN Stock Analysis: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$14.99
-0.57 (-3.66%)
▼
5d:
+1.08%
30d:
+28.89%
90d:
+36.15%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DSGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DSGN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $14.99, which is considered extended relative to its 30-day fair value range of $12.10 to $14.74.
Technical Outlook: Technically, DSGN is in a uptrend. Immediate support is located at $13.88, while resistance sits at $16.12. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: DSGN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+40.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DSGN is in a uptrend. Immediate support is located at $13.88, while resistance sits at $16.12. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: DSGN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+40.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.10 -
$14.74
Company Quality Score
33/100
(SELL)
Options IV Signal
43th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
31.2%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 43th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 40.1% below Wall St target ($21.00)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.10 -
$14.74
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.54
(17.0%)
Support & Resistance Levels
Support Level
$13.88
Resistance Level
$16.12
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.41
Wall Street Target
$21.00
(+40.1%)
Share & Embed Analysis
Last updated: August 22, 2026 2:30 PM ET
Data refreshes hourly during market hours. Next update: 3:30 PM
Data refreshes hourly during market hours. Next update: 3:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
